Reports: Ranbaxy ready for U.S. Aricept launch

Ranbaxy Laboratories has won FDA approval for its version of the Alzheimer's drug Aricept and plans to launch it in the U.S. market as early as today, media reports say, in a development that has analysts predicting at least $100 million in sales over the next six months. Report

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.